Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts

[NewsFeeder]

Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts Say

Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.

https://finance.yahoo.com/m/a941ba0...ca/sanofi-and-regeneron-stocks.html?.tsrc=rss